Ocular Therapeutix Inc. (OCUL) Trading Down 5.4%
Ocular Therapeutix Inc. (NASDAQ:OCUL) shares were down 5.4% on Tuesday . The stock traded as low as $4.75 and last traded at $4.75, with a volume of 149,676 shares traded. The stock had previously closed at $5.02.
Several research analysts have recently weighed in on OCUL shares. Morgan Stanley reissued a “buy” rating on shares of Ocular Therapeutix in a research report on Thursday, May 12th. Royal Bank Of Canada reissued an “outperform” rating and issued a $48.00 target price on shares of Ocular Therapeutix in a research report on Sunday, April 10th. Zacks Investment Research downgraded shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. Finally, Cowen and Company reissued a “buy” rating on shares of Ocular Therapeutix in a research report on Monday, June 6th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $31.85.
The stock’s market capitalization is $120.12 million. The stock has a 50 day moving average of $6.30 and a 200 day moving average of $8.48.
Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.01. The company had revenue of $458 million for the quarter. Equities research analysts predict that Ocular Therapeutix Inc. will post ($1.86) EPS for the current year.
In other Ocular Therapeutix news, CEO Amarpreet Sawhney bought 10,000 shares of the stock in a transaction on Thursday, June 9th. The stock was purchased at an average price of $6.70 per share, with a total value of $67,000.00. Following the acquisition, the chief executive officer now owns 573,733 shares of the company’s stock, valued at $3,844,011.10. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.